^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

EX103

i
Other names: EX103
Company:
ExcelMab
Drug class:
CD20 inhibitor, CD3 agonist
Related drugs:
10ms
Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=415, Recruiting, Guangzhou Excelmab Inc. | Phase classification: P1 --> P1/2 | N=138 --> 415
Phase classification • Enrollment change
|
CD20 positive
|
EX103
12ms
EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma (ASH 2023)
Furthermore, EX103 demonstrates promising efficacy in heavily pretreated patients with R/R B-NHL, including some who have previously failed CAR-T treatment. The safety and efficacy of EX103 will be further evaluated in an ongoing clinical study.
Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6)
|
IL6-L
|
EX103
over1year
EX103, a re-designed CD20xCD3 bispecific antibody, showed a favorable safety and potent single-agent antitumor activity in heavily pretreated relapsed/refractory patients with B cell non-Hodgkin lymphoma (ESMO 2023)
The preliminary Disease Control Rate (DCR) is 84.6% (11/13). Conclusions The preliminary data show favorable safety and remarkable antitumor activity, even at low doses, in heavily pretreated patients with R/R B-NHL, including those who failed prior CAR-T therapy.
Clinical
|
IL6 (Interleukin 6)
|
IL6-L
|
EX103